Economic information and modeling report
Modeling overview
6 evidence topics · 7 sources
Summary
No budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found, and no price for it has been published. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then”, and its presentation describes first-line recurrent or metastatic HPV-negative HNSCC as “a global commercial opportunity of ~$5B+ annually by 2030”. Three published U.S. payer models address first-line comparators. Borse et al. (2022) used a three-state partitioned-survival model over 20 years with 3% annual discounting: pembrolizumab monotherapy was dominant versus the EXTREME regimen in the CPS ≥1 population, and pembrolizumab combination therapy was cost-effective versus EXTREME at $1769/QALY in the overall population. In the Markov model of She et al. (2022), pembrolizumab plus chemotherapy versus cetuximab plus chemotherapy yielded ICERs of $147876.14, $134237.84, and $153660.78 per QALY in the total, CPS ≥1, and CPS ≥20 populations. Ye et al. (2024), using a 15-year three-state partitioned survival model, found the EXTREME regimen cost-effective compared with nivolumab plus ipilimumab at a willingness-to-pay threshold of $150,000/QALY. None of these models includes ficerafusp alfa.
Budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa
No evidence found.
Company statements on pricing and launch timing of ficerafusp alfa
Company estimate of the market for first-line treatment of recurrent or metastatic HPV-negative disease
Cost-effectiveness of first-line pembrolizumab regimens from a United States payer perspective
“Using public drug prices, from a US payer perspective, we evaluated the cost-effectiveness of each pembrolizumab regimen vs. cetuximab + platinum+5-FU (EXTREME regimen, trial comparator), cisplatin + docetaxel + cetuximab (TPEx regimen), cisplatin + paclitaxel, and platinum+5-FU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“First-line pembrolizumab monotherapy in patients with CPS ≥1, and pembrolizumab combination therapy in the overall R/M HNSCC population is cost-effective from the perspective of the US payers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy
“First-line treatment with pembrolizumab or pembrolizumab plus chemotherapy are cost-effective strategies compared with cetuximab plus chemotherapy when the value of willingness-to-pay (WTP) was $150000 per QALY for the total and PD-L1 CPS ≥ 1 populations with recurrent or metastatic HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line nivolumab plus ipilimumab versus the EXTREME regimen
“The EXTREME regimen is cost-effective compared with nivolumab plus ipilimumab for all randomly assigned populations with R/M SCCHN at a WTP threshold of $150,000/QALY from the payer's perspective in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote